AEON Biopharma | 10-Q: Quarterly report

SEC announcement04:46 · Announcements

AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.17) per share which missed the analyst consensus estimate of $(0.31) by 922.58 percent.

Benzinga04:29

Press Release: AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Reports First Quarter 2024 Financial Results -- Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary e

Dow Jones04:05

AEON Biopharma | 10-K/A: Annual report (Amendment)

SEC announcementMay 14 21:09 · Announcements

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner

Yahoo FinanceMay 9 21:35

AEON Biopharma Provides Update on Development Pipeline

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for

GlobeNewswireMay 9 20:00